Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2
Shirley Shapiro Ben David, Israel Potasman, Daniella Rahamim-Cohen
Abstract
This study establishes rates of Guillain-Barré syndrome relapse among Pfizer-BioNTech BNT162b2 vaccine receivers.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Guillain-Barre syndromeSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakMedicineVirologyPediatricsInternal medicineInfectious disease (medical specialty)DiseaseOutbreakPeripheral Neuropathies and DisordersHereditary Neurological DisordersLong-Term Effects of COVID-19